Convatec expands its Lexington R&D facility, part of $1B+ global investment, to boost innovation and strengthen US market ...

A developer has filed plans to turn the former site of the radio station for Kiss 108 into a multifamily residential building ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Vertex Minerals Ltd. ( (AU:VTX)) just ...

Mike Tirico, left, and Cris Collinsworth, right, will call Sunday night's Chiefs-Giants game. / Tim Fuller-Imagn Images NFL fans, are you ready for another weekend of broadcast booth antics, announcer ...

Disappointing trial results for VX-993 led to a sell-off of Vertex's stock recently. The company's financials remain strong, and sales were up 12% last quarter. Vertex has been broadening its pipeline ...

Vertex, Inc. (NASDAQ:VERX) reported weaker-than-expected sales for the second quarter and cut its FY25 sales guidance below estimates on Wednesday. Vertex reported quarterly earnings of 15 cents per ...

(Bloomberg) -- Vertex Pharmaceuticals Inc. fell after an experimental pain drug failed to benefit patients after surgery and US regulators said they didn’t see a path forward for broad use of its pill ...

Vertex Pharmaceuticals Inc. fell after an experimental pain drug failed to provide post-surgery benefits and US regulators said they didn’t see a path forward for broad use of its pill in treating a ...

Vertex Pharmaceuticals (VRTX) came out with quarterly earnings of $4.52 per share, beating the Zacks Consensus Estimate of $4.24 per share. This compares to a loss of $12.83 per share a year ago.

Vertex Pharmaceuticals is the global leader in cystic fibrosis treatment -- and that’s set to continue thanks to the company's innovation. The company recently has expanded into another area, too, and ...

The first quarter of 2025 has presented a complex operating environment for Vertex, as global trade tensions and tariff uncertainties have developed. These occurrences have introduced new headwinds ...

Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) were sinking 11.9% as of 10:18 a.m. ET on Tuesday. The sharp decline came after the company announced its 2025 first-quarter results on Monday evening.